Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients

While patients and physicians seem to have realistic risk perception of PML and knowledge of risk stratification concepts, the threat of MS and the perception of treatment benefits may explain the ongoing high acceptance of PML risk.